Special Issue "Tubulin Inhibitors"
Deadline for manuscript submissions: closed (20 December 2016)
Prof. Dr. Wei Li
Faculty Director of Instrument Facility, University of Tennessee Health Science Center, 881 Madison Avenue, room 561, Memphis, TN 38163, USA
Website | E-Mail
Phone: 901-448-7532 (office), 901-340-9109 (cell)
Interests: small molecule drug discovery; chemical biology; medicinal chemistry; tubulin inhibitors; colchicine binding site inhibitors; non-calcemic vitamin D analogs; survivin inhibitors
Despite the recent advances of targeted therapies (mainly for cancer), chemotherapy will continue to be a broadly effective option and/or addition to targeted therapy in disease treatment. Targeting tubulin dynamics have been proven to be one of the most broadly effective methods in drug development. Currently, there are several clinically available tubulin inhibitors, including paclitaxel, docetaxel, Ixabepilone, cabazitaxel, vincristine, and colchicine. These classes of drugs have been proven to be highly useful clinically, with paclitaxel being the most widely prescribed anticancer drug.
However, there are also limitations in using many of these drugs, including toxicities associated with their systemic administration, susceptibilities to drug efflux pumps, and generally poor bioavailability. There is a constant need for access to novel tubulin inhibitors that can overcome these clinic limitations, or development of unconventional formulations that can reduce systemic toxicities to increase the therapeutic indexes of existing tubulin inhibitors. Significant advances have been made in tubulin inhibitors, with multiple new compounds undergoing clinical trials and the FDA approval of novel formulations (e.g., Abraxane, a nanoparticle formulation of paclitaxel). This Special Issue aims to provide a forum for the dissemination of the latest information on the development of new tubulin inhibitors, new formulations, increased understanding of their mechanisms, and clinical applications.
Prof. Dr. Wei Li
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tubulin dynamics
- tubulin inhibitors
- multidrug resistance
- nanoparticle formulations
- beta-tubulin isotypes and drug resistance
- vascular disruption agent